MedTrace Logo

Phase I Comparative Bioavailability Study

NCT00777582 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients

Conditions

Interventions

DRUG

AZD2281

Oral single dose formulation

Sponsors & Collaborators

Principal Investigators

  • Jane Robertson, BSc, MBCHB, MD · AstraZeneca

  • Stan Kaye, Professor · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-27
Primary Completion
2009-02-06
Completion
2027-03-31

Countries

  • Australia
  • Belgium
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00777582 on ClinicalTrials.gov